Literature DB >> 15174027

Adult-onset ataxia telangiectasia due to ATM 5762ins137 mutation homozygosity.

Ian J Sutton1, James I K Last, Susan J Ritchie, Hugh J Harrington, Philip J Byrd, A Malcolm R Taylor.   

Abstract

Ataxia telangiectasia (A-T) is an autosomal recessive neurodegenerative disorder that arises because of mutations in the ATM gene. The 5762ins137 A-->G point mutation activates a cryptic splice donor site resulting in a 137 bp intronic insert being aberrantly spliced into the ATM transcript. However, normal ATM transcript also is produced from this affected allele, albeit at significantly reduced levels. An exceptionally mild A-T phenotype occurs as a result of homozygosity for the 5762ins137 mutation because of relative preservation of ATM protein expression/kinase activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15174027     DOI: 10.1002/ana.20139

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

1.  Exclusion/confirmation of ataxia-telangiectasia via cell-cycle testing.

Authors:  Tilman Heinrich; Carolin Prowald; Richard Friedl; Benni Gottwald; Reinhard Kalb; Kornelia Neveling; Sabine Herterich; Holger Hoehn; Detlev Schindler
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

Review 2.  Molecular pathology of ataxia telangiectasia.

Authors:  A M R Taylor; P J Byrd
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

3.  Autosomal recessive adult onset ataxia.

Authors:  Nataša Dragašević-Mišković; Iva Stanković; Andona Milovanović; Vladimir S Kostić
Journal:  J Neurol       Date:  2021-09-09       Impact factor: 4.849

4.  Compound heterozygous variants including a novel copy number variation in a child with atypical ataxia-telangiectasia: a case report.

Authors:  Hoo Young Lee; Dae-Hyun Jang; Jae-Won Kim; Dong-Woo Lee; Ja-Hyun Jang; Joungsu Joo
Journal:  BMC Med Genomics       Date:  2021-08-17       Impact factor: 3.063

5.  Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene.

Authors:  E R Staples; E M McDermott; A Reiman; P J Byrd; S Ritchie; A M R Taylor; E G Davies
Journal:  Clin Exp Immunol       Date:  2008-05-26       Impact factor: 4.330

6.  Variant ataxia telangiectasia: clinical and molecular findings and evaluation of radiosensitive phenotypes in a patient and relatives.

Authors:  Kathleen Claes; Julie Depuydt; A Malcolm R Taylor; James I Last; Annelot Baert; Peter Schietecatte; Veerle Vandersickel; Bruce Poppe; Kim De Leeneer; Marc D'Hooghe; Anne Vral
Journal:  Neuromolecular Med       Date:  2013-04-30       Impact factor: 3.843

7.  Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours.

Authors:  A Reiman; V Srinivasan; G Barone; J I Last; L L Wootton; E G Davies; M M Verhagen; M A Willemsen; C M Weemaes; P J Byrd; L Izatt; D F Easton; D J Thompson; A M Taylor
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

8.  Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia.

Authors:  P J Byrd; V Srinivasan; J I Last; A Smith; P Biggs; E F Carney; A Exley; C Abson; G S Stewart; L Izatt; A M Taylor
Journal:  Br J Cancer       Date:  2011-12-06       Impact factor: 7.640

9.  Ten new ATM alterations in Polish patients with ataxia-telangiectasia.

Authors:  Marta Joanna Podralska; Agnieszka Stembalska; Ryszard Ślęzak; Aleksandra Lewandowicz-Uszyńska; Barbara Pietrucha; Sylwia Kołtan; Jadwiga Wigowska-Sowińska; Jacek Pilch; Maria Mosor; Iwona Ziółkowska-Suchanek; Agnieszka Dzikiewicz-Krawczyk; Ryszard Słomski
Journal:  Mol Genet Genomic Med       Date:  2014-07-30       Impact factor: 2.183

Review 10.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.